If you’ve recently picked up the phone to refill your estrogen patch and been told it’s on backorder, you are definitely not alone. There is, at the time of this article, a nation-wide shortage for the Estradiol patch. Across Virginia Beach and the wider Hampton Roads area, more women are running into the same conversation at the pharmacy counter, and many of them are walking away worried that the medication they started to depend on is now suddenly out of reach.
We want to start with the most important thing we can tell you. The medication itself is not gone. What’s happening in 2026 right now is more accurately described as a physical patch shortage, not an estradiol shortage. That small distinction changes what your options are.
The Real Story Behind the Shortage
The estradiol shortage that’s been in the news is concentrated in transdermal patches, which delivers estrogen directly through the skin. Brands like Dotti, Lyllana, Climara, Vivelle-Dot, and several generics have all been affected by manufacturing constraints, and pharmacy supply has not been able to keep pace with demand. That part of the story is completely real, and what you are seeing at the counter when you go to refill your prescription.
What hasn’t been emphasized as clearly in the news is that estradiol itself, the active hormone, remains widely available in other forms. Oral estradiol is in stable supply. Topical estradiol creams, particularly those compounded for individual patients, are not subject to the same manufacturing bottleneck. Vaginal estrogen and other delivery formats remain accessible for the women who need them.
The shortage is a story about how patches are made, not about whether estradiol can be prescribed.
Why the Shortage Happened
Hormone therapy demand has grown significantly over the past several years, and that growth accelerated following the FDA’s decision in November 2025 to revise its longstanding black box warnings on menopausal hormone therapy. The practical effect has been a wave of new conversations about HRT that weren’t happening five years ago. Women who had been told for decades that hormone therapy carried risks outweighing its benefits are now, often for the first time, being told the opposite by their doctors.
The challenge is that the manufacturing system supporting estradiol patches was built around the previous, much smaller demand level. Transdermal patches are also one of the more technically demanding pharmaceutical formats to produce. They require specialized facilities and a small group of manufacturers who hold the necessary equipment and expertise. When demand surges, those manufacturers cannot scale up overnight, and meaningful production increases can take many months.
This is the situation most women find themselves in when their pharmacy says the patch is unavailable. It’s not that the medical community has lost confidence in estradiol. It’s that one specific way of delivering it is temporarily harder to source.
Estradiol Was Never Just the Patch
This is where the conversation often stops short in primary care, and it’s the part we’d most like every woman currently navigating a refill issue to understand.
Estradiol can be delivered through several different routes, each with its own clinical considerations. Oral estradiol is taken as a tablet and is widely available. Topical estradiol creams allow the hormone to be absorbed through the skin without a patch, and when prepared by an accredited compounding pharmacy, the dose can be precisely tailored to the individual patient. Vaginal estrogen serves a different and more localized role, often for genitourinary symptoms of menopause, and remains in stable supply.
The patch became the default option in many primary care settings because it was familiar, FDA approved, and easy to prescribe in a brief appointment. That isn’t a criticism of primary care, it’s an observation about how complicated hormone therapy gets when you take the whole patient into account.
A women’s hormone optimization specialist evaluates symptoms, lab values, body composition, age, lifestyle choices, and personal preference together before recommending a delivery method. For many women, the resulting treatment plan looks meaningfully different from what they were initially handed.
The Role of Compounded Estradiol
One of the most significant clinical advantages available right now, in the middle of this shortage, is access to compounded estradiol creams prepared by accredited compounding pharmacies. Pharmacies that hold proper credentials, such as PCAB accredited 503A pharmacies like MedQuest/Belmar, can prepare estradiol in concentrations tailored to the individual patient.
This is something the commercial supply chain cannot do. Every commercial patch in a given strength delivers the same dose to every patient, regardless of how that patient absorbs medication, what their body composition looks like, or what their symptom profile actually is. Compounding allows a provider to adjust strength, base, and application protocol to match the patient. For women whose previous patch dose was either too low or too high to fully resolve their symptoms, compounding often produces noticeably better results.
We work with compounding pharmacies Dr. Gershon selects and trusts based on quality, consistency, and clinical track record. The benefit of practicing this way is flexibility. When supply chain issues affect one delivery format or product, we have other clinically appropriate options ready, and the patient experience remains continuous. This kind of individualization is part of what distinguishes bioidentical hormone therapy from mass-produced alternatives, and it remains available even when commercial patch supply tightens.
What This Means for Perimenopausal and Menopausal Women
Hormone therapy is not only a postmenopausal conversation. Many women in perimenopause experience symptoms that respond well to hormone optimization, and the same flexibility in delivery options applies. The challenge is that perimenopause and menopause are often confused, and that confusion can delay treatment for women who would benefit from starting earlier.
The thread connecting all of this is simple. Hormone therapy is more individualized than the public conversation often suggests, and a patch shortage doesn’t change that. It just makes the individualization more visible.
If You’ve Only Been Offered the Patch, You May Not Have Been Offered the Full Picture
Here is what we’d most like every woman in Virginia Beach reading this to take away.
If your only option for hormone therapy has been the patch, if your prescription has suddenly become difficult to fill, or if your symptoms aren’t fully resolved on your current dose, a consultation with a hormone specialist may be worthwhile. This isn’t about replacing your primary care provider. It’s about getting a second set of eyes on a treatment decision that benefits from specialty expertise.
Hormone therapy is, in our experience, one of the areas of medicine where individualized evaluation matters most. Two women with similar symptoms can need very different protocols, and the difference between adequate symptom relief and feeling like yourself again often comes down to dose, delivery, and the willingness to adjust both based on how the patient is actually responding.
If you’d like to talk through your options, we’d be glad to hear from you.
Common Questions We’re Hearing
Is the estradiol shortage permanent?
No. The shortage affects estradiol patch supply specifically, and it’s the result of demand growing faster than manufacturers can scale production. Estradiol itself, in oral, topical, and compounded forms, remains widely available.
Can I switch from a patch to a cream without losing symptom control?
For most women, yes. The transition is usually smoothest under the guidance of a hormone specialist who can match the new dose to your prior treatment and monitor your symptom response over the following weeks.
Are compounded hormones safe?
When prepared by an accredited compounding pharmacy and prescribed by a qualified provider, compounded bioidentical hormones are a long-established, clinically appropriate option. The key factors are the credentials of the pharmacy and the experience of the prescribing physician.
Should I keep using my patch if I can find one in stock?
If your current treatment is working well, there’s no reason to switch. The point of this article isn’t that the patch is wrong, it’s that it isn’t the only option, and women whose patches have suddenly become unavailable have other paths forward.
